---
input_text: 'In-depth Clinical and Biological Exploration of DNA Damage Immune Response
  as a Biomarker for Oxaliplatin Use in Colorectal Cancer. PURPOSE: The DNA damage
  immune response (DDIR) assay was developed in breast cancer based on biology associated
  with deficiencies in homologous recombination and Fanconi anemia pathways. A positive
  DDIR call identifies patients likely to respond to platinum-based chemotherapies
  in breast and esophageal cancers. In colorectal cancer, there is currently no biomarker
  to predict response to oxaliplatin. We tested the ability of the DDIR assay to predict
  response to oxaliplatin-based chemotherapy in colorectal cancer and characterized
  the biology in DDIR-positive colorectal cancer. EXPERIMENTAL DESIGN: Samples and
  clinical data were assessed according to DDIR status from patients who received
  either 5-fluorouracil (5-FU) or 5FUFA (bolus and infusion 5-FU with folinic acid)
  plus oxaliplatin (FOLFOX) within the FOCUS trial (n = 361, stage IV), or neoadjuvant
  FOLFOX in the FOxTROT trial (n = 97, stage II/III). Whole transcriptome, mutation,
  and IHC data of these samples were used to interrogate the biology of DDIR in colorectal
  cancer. RESULTS: Contrary to our hypothesis, DDIR-negative patients displayed a
  trend toward improved outcome for oxaliplatin-based chemotherapy compared with DDIR-positive
  patients. DDIR positivity was associated with microsatellite instability (MSI) and
  colorectal molecular subtype 1. Refinement of the DDIR signature, based on overlapping
  IFN-related chemokine signaling associated with DDIR positivity across colorectal
  cancer and breast cancer cohorts, further confirmed that the DDIR assay did not
  have predictive value for oxaliplatin-based chemotherapy in colorectal cancer. CONCLUSIONS:
  DDIR positivity does not predict improved response following oxaliplatin treatment
  in colorectal cancer. However, data presented here suggest the potential of the
  DDIR assay in identifying immune-rich tumors that may benefit from immune checkpoint
  blockade, beyond current use of MSI status.'
raw_completion_output: |-
  primary_disease: Colorectal Cancer

  medical_actions: DNA damage immune response (DDIR) assay development; Oxaliplatin-based chemotherapy; 5-fluorouracil (5-FU) treatment; FOLFOX regimen administration; Neoadjuvant therapy; Immune checkpoint blockade

  symptoms: Microsatellite instability (MSI)

  chemicals: Oxaliplatin; 5-fluorouracil (5-FU); Folinic acid

  action_annotation_relationships: DDIR assay development TREATS microsatellite instability (MSI) IN Colorectal Cancer; Oxaliplatin-based chemotherapy TREATS Colorectal Cancer; 5-fluorouracil (5-FU) treatment TREATS Colorectal Cancer; FOLFOX regimen administration (with Oxaliplatin; 5-fluorouracil (5-FU); Folinic acid) TREATS Colorectal Cancer; Neoadjuvant therapy TREATS Colorectal Cancer; Immune checkpoint blockade PREVENTS microsatellite instability (MSI) IN Colorectal Cancer
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Immune checkpoint blockade PREVENTS microsatellite instability (MSI) IN Colorectal Cancer

  ===

extracted_object:
  primary_disease: MONDO:0005575
  medical_actions:
    - DNA damage immune response (DDIR) assay development
    - Oxaliplatin-based chemotherapy
    - 5-fluorouracil (5-FU) treatment
    - FOLFOX regimen administration
    - Neoadjuvant therapy
    - Immune checkpoint blockade
  symptoms:
    - Microsatellite instability (MSI)
  chemicals:
    - CHEBI:31941
    - CHEBI:46345
    - CHEBI:15640
  action_annotation_relationships:
    - subject: assay development
      predicate: TREATS
      object: microsatellite instability (MSI)
      qualifier: MONDO:0005575
      subject_qualifier: DDIR
      subject_extension: DDIR assay
    - subject: MAXO:0000647
      predicate: TREATS
      object: Colorectal Cancer
      subject_qualifier: based
      subject_extension: CHEBI:31941
    - subject: treatment
      predicate: TREATS
      object: Colorectal Cancer
      subject_extension: CHEBI:46345
    - subject: FOLFOX regimen administration
      subject_qualifier: with Oxaliplatin
      subject_extension: CHEBI:31941
    - subject: Folinic acid
      predicate: TREATS
      object: Colorectal Cancer
    - subject: Neoadjuvant therapy
      predicate: TREATS
      object: Colorectal Cancer
    - subject: <Immune checkpoint blockade>
      predicate: <PREVENTS>
      object: <microsatellite instability>
      qualifier: <Colorectal Cancer>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <Immune checkpoint blockade>
      object_extension: <microsatellite instability (MSI)>
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
  - id: HP:0000568
    label: Microphthalmia
  - id: HP:0000482
    label: microcornea
  - id: HP:0000508
    label: ptosis
  - id: HP:0011496
    label: limbal neovascularization
  - id: HP:0001097
    label: keratoconjunctivitis sicca
  - id: CHEBI:62932
    label: Mycophenolate
  - id: MONDO:0008903
    label: Lung Cancer
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0032169
    label: severe infections
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: MONDO:0005109
    label: HIV
  - id: HP:0001622
    label: Preterm delivery
  - id: HP:0100601
    label: Eclampsia
  - id: MONDO:0043455
    label: Hereditary hematological malignancy (HHM)
  - id: MONDO:0043797
    label: Spinal Cord Injury (SCI)
  - id: CHEBI:27306
    label: Vitamin B6
  - id: HP:0001915
    label: aplastic anemia
  - id: MONDO:0001056
    label: Gastric cancer
  - id: MAXO:0001193
    label: Esophagogastroduodenoscopy
  - id: CHEBI:31941
    label: Oxaliplatin
  - id: HP:0012126
    label: Gastric cancer
  - id: MONDO:0005575
    label: Colorectal Cancer
  - id: CHEBI:46345
    label: 5-fluorouracil (5-FU)
  - id: CHEBI:15640
    label: Folinic acid
